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Electrospray ionization (ESI) is a soft ionization technique that is able to transfer intact ions, as
well as solution phase non-covalent complexes into the gas phase. With small molecules that
have a high tendency to form hydrogen bonds, the observation of non-covalent complexes by
ESI-MS can be the result of a non-specific interaction, due to the nature of the electrospray
process. Special precautions and additional steps should be performed to identify the origin of
the complexes observed with ESI-MS, and we have utilized solution phase hydrogen/
deuterium (H/D) exchange as a method to determine the specificity of the complexes. By
comparing the average number of exchanges for the monomer subunits to the average number
of exchanges for the complex, one can distinguish if a specific complex is formed in solution.
In this paper we have investigated non-covalent complexes of some common chemotherapy
agents: paclitaxel, doxorubicin, and etoposide by ESI-MS. By using the solution phase H/D
exchange, we were able to identify several specific drug–drug complexes. Thus, solution phase
H/D exchange combined with ESI-MS provides for a convenient method in ascertaining the
specificity of non-covalent complexes as being formed in solution or in vacuo. (J Am Soc
Mass Spectrom 2001, 12, 795-804) © 2001 American Society for Mass Spectrometry
Electrospray ionization (ESI) is a soft ionizationtechnique that allows for the transfer of non-covalent complexes from the solution phase to
the gas phase. In order to preserve non-covalent inter-
actions present in solution, ESI experimental conditions
must be sufficiently gentle yet must be sufficiently
harsh for ion desolvation to occur. Solution conditions,
such as the presence of buffers and/or organic solvents,
temperature, and pH, can also influence the conserva-
tion of non-covalent complexes. ESI-MS has been used
to study a wide variety of non-covalent interactions
including receptor–ligand complexes [1], enzyme com-
plexes [2–5], protein–protein interactions and protein–
ligand complexes [6–21], quartenary protein structure
[22–24], oligonucleotide complexes [25–28], DNA qua-
druplexes [29], and duplex DNA–drug complexes [30].
The observation of non-covalent complexes by
ESI-MS should always be approached with some cau-
tion. Non-covalent complexes usually involve interac-
tions through hydrogen bonding, and the molecules
tend to have a high affinity to hydrogen bond to solvent
and/or other molecules present. Complexes involving
multiply-charged ions from each subunit (e.g., protein
dimers, DNA duplexes) are almost certainly formed in
solution because Coulombic repulsion effectively pre-
vents two highly-charged species from coming together
during the ESI process. However, not all non-covalent
complexes involve two highly-charged subunits. For
example, the ligand in protein–ligand complexes may
not be charged; therefore, Coulombic repulsion would
not prevent formation of such complexes during the ESI
process. Two important questions arise: (1) how do
non-specific complexes form? (2) how might it be
possible to distinguish nonspecific associations with
non-covalent complexes formed in solution prior to
ESI?
An important point to note is that as ESI progresses,
charged droplets become smaller because of solvent
evaporation, and the ion concentration increases in the
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droplet. Is it the removal of solvent which produces a
non-specific interaction? This is an issue that must be
considered when studying non-covalent complexes by
ESI-MS, and was addressed by Smith et al. in a review
paper about the observation of non-covalent complexes
by ESI [31]. Adjustment of the interface parameters to
obtain mass spectra where the complex dominates over
the dissociated species is good evidence for a specific
association in solution. Also, if the stoichiometry ob-
tained with ESI-MS agrees with previous literature on
the complex, this supports (but does not prove) the
findings of a specific non-covalent complex formed in
the solution phase and transferred to the gas phase via
ESI. For example, if previous findings showed a dimer
and a tetramer only for the complexes, and the ESI mass
spectrum shows a dimer, trimer, tetramer, and pen-
tamer, then non-specific associations are clearly being
observed. Non-covalent complexes involve weak inter-
actions, such as hydrogen bonding, and therefore
should be labile. These complexes should readily dis-
sociate under harsher interface conditions or tandem
mass spectrometry experiments. Changes in the solu-
tion conditions (pH, temperature, buffer components,
and organic solvents) can disrupt a specific interaction
in solution, and therefore will produce a change in the
ESI mass spectrum. Varying one of the complex com-
ponents should also produce a substantial change in the
relative intensity of the complex in the mass spectrum.
For example, if a certain protein–ligand complex is
being studied, the protein sequence can be slightly
modified. If the association of the protein and ligand is
specific, the modification of the protein sequence will
lead to lower specificity and a decrease in intensity (of
the complex) in the ESI mass spectrum.
However, a potentially powerful method in elucidat-
ing the solution or gas phase formation of non-covalent
complexes is solution phase H/D exchange. The ex-
change of hydrogen atoms by deuterium is commonly
used to provide three-dimensional structural informa-
tion. It has been used in MS both in the solution phase
[32–34] and the gas phase [35–39]. We are interested in
determining whether solution phase molecular interac-
tions of pharmaceutical drugs exist; therefore, here we
utilized solution phase H/D exchange. By comparing
the average number of H/D exchanges for the individ-
ual units comprising the complex with the number of
H/D exchanges in the complex itself provides useful
information about the complex origin. If a complex is
formed during ESI, the average number of H/D atoms
exchanged in a complex should equal the sum of the
number of H/D atoms exchanged in each of the com-
ponents. This does not preclude the possibility of
dimerization in solution; indeed, if H/D exchange is
rapid relative to the process of dimerization, dimers
will also show twice the exchange level as the mono-
mers. However, if the total number of H/D atoms
exchanged in a complex is lower than the sum of H/D
atoms exchanged in each of its components, this is
strong evidence that the complex was formed in solu-
tion prior to ESI. This is a consequence of some atoms in
the complex being protected from isotope exchange.
Here, we explore the interaction of three common chemo-
therapy agents—paclitaxel, doxorubicin, and etoposide—
using ESI mass spectrometry. Doxorubicin and etoposide
are used frequently in combination chemotherapy regi-
mens with paclitaxel. The dimerization of paclitaxel by
ESI-MS will be discussed in a separate report [40]. Here,
doxorubicin and etoposide exhibit aggregates in ESI-MS;
the specificities of these complexes (formed in solution or
in the gas phase) were explored with solution phase H/D
exchange. Heteromeric non-covalent complexes of
these three drugs in two-drug mixtures were observed
with ESI-MS, and the technique of solution phase H/D
exchange was utilized to evaluate which of these com-
plexes might originate in solution phase. In some cases,
H/D exchange suggests that the drug–drug complexes
observed in the mass spectra are formed in solution.
However, in other instances the total number of hydro-
gen isotopes exchanged for deuterium in the complex is
identical (within experimental error) to the sum of the
exchanges in each of the components; in these cases, the
drug–drug complexes observed are most likely non-
specific associations formed during ESI.
Experimental
ESI-FTMS Instrumentation
All work was performed on a commercial Bruker Dal-
tonics BioApex 30es (Billerica, MA) Fourier-transform
mass spectrometer (FTMS). The instrument is equipped
with a 3 tesla Magnex (Abingdon, UK) 160 mm hori-
zontal bore superconducting magnet, an Analytica of
Branford (Branford, CT) electrospray source, and an
Infinity Cell [41]. The external ESI source is the same as
previous descriptions [42–45] and includes an (IRIS)
hexapole ion guide. Ion accumulation in the Infinity
Cell (2.0 V trapping potential) is achieved using the
Sidekick method [46]. Frequency-sweep excitation from
m/z 100–2000 was applied at an amplitude of ;44–63
Vp-p, and detection was in the direct mode (500 kHz
Nyquist bandwidth) from 128K time domain data sets
(25 acquisitions per experiment). The data was Fourier
transformed and displayed in magnitude mode. All
FTMS event sequences are controlled by Bruker’s
XMASS software on a Silicon Graphics (Mountain
View, CA) INDY 100 MHz R4600PC computer with 32
MB RAM. Samples were continuously introduced to the
electrospray source with a Cole-Parmer Series 74900
infusion pump at a flow rate of 60 mL/hr.
Sample Preparation
The three drugs used in this study are all shown in
Figure 1. Solid paclitaxel (molecular weight 853 Da, four
exchangeable H atoms) was obtained from Hauser
Chemical Research Inc. (Boulder, CO). Solid doxorubi-
cin (molecular weight 543 Da, seven exchangeable H
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atoms) and etoposide (molecular weight 588 Da, three
exchangeable H atoms) were obtained from Sigma (St.
Louis, MO) and used with no further purification.
HPLC-grade acetonitrile, water, and acetic acid were
used in the preparation of all solutions. Deuterium
oxide was obtained from Cambridge Isotope Laborato-
ries (Woburn, MA). Stock solutions of the three drugs
were prepared and stored in the refrigerator at 2 °C
until needed.
Solution Phase H/D Exchange
Samples of doxorubicin (16 mg/mL concentration) and
paclitaxel (8 mg/mL concentration) were prepared in
acetonitrile/water/acetic acid (80/18/2, v/v/v), with
one of the samples containing 100 mL of D2O. The
deuterated sample was allowed to exchange for approx-
imately 90 min before being analyzed by ESI-FTMS. The
non-deuterated and deuterated samples were analyzed
under identical experimental conditions, and the result-
ing mass spectra were compared. The average masses
of the ions were calculated using eq. 1:
MAvg 5 SRA~M1!TA DM1 1 SRA~M2!TA DM2
1 . . .SRA~Mn!TA DMn (1)
where Mavg is the average mass of the ion, RA is the
relative abundance of a given isotopic peak, TA is the
total relative abundance for all of the isotopic peaks in
the distribution, and M1, M2,…Mn are the masses for the
first, second, and n-th peaks in the isotopic distribution.
The average masses for the non-deuterated species
were subtracted from the average masses of the deuter-
ated species, and the average number of H/D ex-
changes was determined by dividing this mass differ-
ence by the isotopic mass difference between D and H
(1.006 Da). The reported errors of exchange level repre-
sent one standard deviation from the mean determined
from five replicate measurements on each individual
sample. Summing acquisitions effectively averages out
random errors associated with variation in isotopic
peak abundance due to fluctuations in trapped ion
populations.
Using the same experimental approach, ESI-FTMS
mass spectra were obtained for samples of: etoposide
(16 mg/mL), etoposide and paclitaxel (16 mg/mL and 8
mg/mL concentrations, respectively), and doxorubicin
and etoposide (both 16 mg/mL). The solvent mixture in
these cases was always 80% acetonitrile/18% water/2%
acetic acid (v/v/v). H/D exchange was conducted and
five replicate measurements of the same sample were
acquired after 90 6 10 min. The error in the time
measurement depends upon sample loading into the
Figure 1. Structures of paclitaxel, doxorubicin, and etoposide.
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ESI source and the time it took before signal was
actually detected. It should also be noted that each set of
experiments was acquired on completely different days;
this could account for the variability between H/D
exchange levels for the same molecular species between
runs, especially because H/D exchange is highly sensi-
tive to environmental relative humidity, which can
cause D-to-H back exchange and influence overall H/D
levels.
Results and Discussion
Doxorubicin Aggregates and
Doxorubicin–Paclitaxel Aggregates: Formed in
Solution or the Gas Phase?
As shown in Figure 2, doxorubicin (8 mg/ml) in aceto-
nitrile with 2% acetic acid yielded a mass spectrum of
the singly-protonated monomer (m/z 544), the singly-
protonated dimer (m/z 1087), and the singly-protonated
trimer (m/z 1630). Doxorubicin is an anthracycline, a
class of compounds known to associate in aqueous
solutions (as opposed to the organic/aqueous solvent at
acidic pH as used here) forming dimeric and higher
order polymeric aggregates [47], as shown by X-ray
diffraction [48], circular dichroism (CD) [49], and nu-
clear magnetic resonance (NMR) [49]. Anguili et al.
studied the X-ray crystal structure of a derivative of the
anthracycline antibiotic, N-Br-acetyl-daunomycin [48].
There was evidence of hydrogen bonding between
daunomycin molecules to form aggregates in the crystal
structure. Barthelemy-Clavey et al. studied the self-
association of daunorubicin in solutions of 0.1 M so-
dium chloride and sodium citrate, pH 7.0 [49]. At
concentrations of daunorubicin ,5 3 1028 M, all the
experimental results are in good agreement with a
dimerization model. From the CD measurements, an
association constant of 570 M21 was obtained, and from
the NMR experiments, 600 M21. At higher concentra-
tions, there is a drastic change in the CD spectra, which
could be explained by the formation of higher order
aggregates with an association constant of approxi-
mately 2 M21. Thus, there is literature evidence of
aggregation of anthracyclines. However, are the doxo-
rubicin dimers and trimers observed here with ESI-MS
really formed in solution?
Doxorubicin mixed with paclitaxel (16 mg/mL and 8
mg/mL respectively, 80% acetonitrile/18% water/2%
acetic acid) resulted in the ESI mass spectrum shown in
Figure 3. Peaks corresponding to the protonated mono-
mer of doxorubicin (m/z 544), the sodium and potas-
sium adducts of the paclitaxel monomer (m/z 876 and
892, respectively), as well as the paclitaxel dimer plus
sodium (m/z 1729) are all observed. The protonated
doxorubicin–paclitaxel heteromeric complex (m/z 1397)
is also observed with high intensity in the mass spec-
trum. After exposing this sample to D2O for 90 min of
isotope exchange, the average number of H/D ex-
changes for the doxorubicin monomer is 2.11 6 0.04
(Figure 4a), while the paclitaxel monomer has an aver-
age number of H/D exchanges equal to 0.57 6 0.04
(Figure 4b). The dimeric doxorubicin complex has a low
level of H/D exchanges at 0.61 6 0.08 (Figure 4c). This
number is less than one-third the total number of H/D
exchanges observed in the doxorubicin monomer. This
Figure 2. ESI-FT mass spectrum of 8 mg/mL doxorubicin in acetonitrile with 2% acetic acid.
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is clear evidence that solution H/D exchange in the
dimer is greatly restricted, implying that the dimer
complex must be formed in solution prior to ESI. In
contrast, the heteromeric doxorubicin–paclitaxel com-
plex has an average number of H/D exchanges equal to
2.75 6 0.02 (Figure 4d). Within experimental error, the
average number of exchanges for the paclitaxel–doxo-
rubicin complex is equivalent to the sum of the number
of exchanges for the doxorubicin monomer and the
paclitaxel monomer (2.75 versus 2.68). Comparison of
Figure 3. ESI-FT mass spectrum of a mixture of doxorubicin (D) and paclitaxel (P).
Figure 4. Insets of isotopic distributions in the doxorubicin–paclitaxel mixture. (a) Protonated
doxorubicin before (top) and after 90 min H/D exchange (bottom). (b) Sodiated paclitaxel before (top)
and after 90 min H/D exchange (bottom). (c) Protonated doxorubicin dimer before (top) and after 90
min H/D exchange (bottom). (d) Protonated doxorubicin–paclitaxel complex before (top) and after 90
min H/D exchange (bottom).
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these two numbers suggests that either (1) the doxoru-
bicin–paclitaxel complex is formed during ESI, and
represents a non-specific interaction, or (2) that solution
dimerization of doxorubicin with paclitaxel is kineti-
cally slow relative to H/D exchange. As desolvation
proceeds during ESI, the concentrations of the drugs are
rapidly increased, so potential doxorubicin–paclitaxel
interactions may be magnified.
Etoposide Aggregates: Formed in Solution or the
Gas Phase?
ESI-MS of etoposide (16 mg/mL, 80% acetonitrile/18%
water/2% acetic acid) shows major peaks at m/z 611 and
1199. These peaks correspond to the sodium adducts of
the etoposide monomer and dimer, respectively, and
are shown in Figure 5. Two low intensity peaks at m/z
1221 and 1243 in Figure 5 correspond to the replace-
ment of hydrogen by sodium in the etoposide dimer.
Solution phase H/D exchange was performed to
determine the origin of the etoposide dimer species. The
average number of exchanges for the etoposide mono-
mer was 1.38 6 0.03 (Figure 6a), while the average
number of exchanges for the etoposide dimer was
2.83 6 0.05 (Figure 6b). The exchange level of the dimer
is, within experimental error, twice that of the mono-
mer. There are two possible interpretations of this
result. One possibility is that the etoposide dimer does
Figure 5. ESI-FT mass spectrum of etoposide.
Figure 6. Insets of isotopic distributions for etoposide. (a) Sodiated etoposide monomer before (top)
and after 90 min H/D exchange (bottom). (b) Sodiated etoposdie dimer before (top) and after 90 min
H/D exchange (bottom).
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not exist as a solution phase aggregate, but instead is a
nonspecific association formed during ESI. The other
possibility is that H/D exchange in etoposide is kinet-
ically fast relative to dimerization. From the experi-
ments performed here it is not possible to establish
which of these two cases is more likely.
Etoposide–Paclitaxel Aggregates: Formed in
Solution or the Gas Phase?
The mass spectrum (Figure 7) of the interaction of
etoposide with paclitaxel (16 mg/mL and 8 mg/mL,
respectively) reveals etoposide (sodiated, m/z 611) and
paclitaxel monomers (protonated at m/z 854, sodium
adduct at m/z 876), the paclitaxel dimer (sodium adduct,
m/z 1729), and the sodiated etoposide–paclitaxel com-
plex (m/z 1464). The etoposide–paclitaxel complex was
also examined after 90 min of H/D exchange. The
average number of H/D exchanges for the etoposide
monomer in this mixture is 0.87 6 0.03 (Figure 8a). The
sodiated paclitaxel monomer shows an average number
of exchanges equal to 0.94 6 0.02 (Figure 8b), while the
average number of exchanges for the heteromeric com-
plex is 1.58 6 0.03 (Figure 8c). Unlike the doxorubicin–
paclitaxel complex, the average number of exchanges
for the etoposide–paclitaxel complex is less than the
sum of the number of exchanges in its constituent
monomers. Therefore, it can be concluded that the
etoposide–paclitaxel complex observed by ESI is the
result of a solution phase interaction. The average
number of exchanges in the paclitaxel dimer is 1.69 6
0.13 (spectrum not shown). This number is slightly less
than twice that observed in the monomer, and is
consistent with previous H/D exchange results in our
laboratory that suggest paclitaxel exists as a solution
phase dimer [40].
Doxorubicin–Etoposide Aggregates: Formed in
Solution or the Gas Phase?
The ESI mass spectrum of the interaction of doxorubicin
with etoposide (both 16 mg/ml) in 80% acetonitrile/
18% water/2% acetic acid (v/v/v) reveals both the
etoposide (sodiated, m/z 611) and protonated doxorubi-
cin monomers, with the doxorubicin–etoposide com-
plex (m/z 1132) dominating the mass spectrum (Figure
9). H/D exchange of the doxorubicin–etoposide mix-
ture was conducted for 90 min. The average number of
exchanges for the doxorubicin monomer is 3.34 6 0.10
(Figure 10a), while the average number of exchanges for
the etoposide monomer is only 1.19 6 0.03 (Figure 10b).
The doxorubicin–etoposide complex shows an average
number of H/D exchanges equal to 4.73 6 0.23 (Figure
10c). Within experimental error, the average number of
exchanges for the complex is equivalent to the sum of
the average number of exchanges for each component;
therefore it may be concluded that (1), the doxorubicin–
etoposide complex represents a non-specific interaction
formed during ESI or (2), that solution-phase het-
erodimerization is slow relative to H/D exchange.
Conclusions
This study illustrates the use of solution phase H/D
exchange to determine the specificity of non-covalent
drug–drug complexes observed by ESI-MS. Compari-
Figure 7. ESI-FT mass spectrum of a mixture of etoposide (E) and paclitaxel (P).
801J Am Soc Mass Spectrom 2001, 12, 795-804 SOLUTION H/D EXCHANGE FOR NON-COVALENT COMPLEXES
son of the number of H/D exchanges in each of the
monomers to the number of exchanges for the complex
can distinguish if an observed complex is formed in
solution. Based on H/D exchange, the doxorubicin
dimer observed in ESI mass spectra was determined to
be a species which forms in solution. Heteromeric
complexes of doxorubicin with paclitaxel and doxoru-
bicin with etoposide were determined to be non-specific
aggregates formed during ESI or possibly solution-
phase species in which dimerization is slow relative to
Figure 8. Insets of isotopic distributions in the etoposide–paclitaxel mixture. (a) Sodiated etoposide
before (top) and after 90 min H/D exchange (bottom). (b) Sodiated paclitaxel before (top) and after 90
min H/D exchange (bottom). (c) Sodiated etoposide–paclitaxel complex before (top) and after 90 min
H/D exchange (bottom).
Figure 9. ESI-FT mass spectrum of a mixture of doxorubicin (D) and etoposide (E).
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H/D exchange. A similar interpretation was made for
the etoposide dimer. However, the etoposide–paclitaxel
complex shows lower H/D exchange than the sum
levels of its monomers, and hence it is likely formed in
solution. Thus, H/D exchange provides for a conve-
nient new method in investigating the specificity of
non-covalent complexes as being formed in solution or
in vacuo.
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